A groundbreaking clinical study has revealed that a novel pharmaceutical combination offers the first promising intervention for early-stage Peyronie’s disease (PD), a debilitating fibrotic condition affecting millions globally. Published in The Journal of Sexual Medicine, this research could signal a paradigm shift in managing PD, moving from symptomatic treatment towards modifying the disease’s underlying pathology through off-label drug repurposing.
Peyronie’s disease is characterized by the aberrant formation of fibrotic scar tissue within the tunica albuginea of the penis. This pathology leads to painful erections, penile curvature, erectile dysfunction, and profound psychological distress for an estimated 10% of men during their lifespan. The etiology involves the transformation of normal fibroblasts into myofibroblasts within the penile tissue, a key driver of fibrotic plaque formation and tissue contracture. Current therapy options, especially in the acute phase of PED, are severely limited, with no approved oral treatments to arrest or reverse fibrotic progression.
This milestone clinical investigation, led by renowned urologists and researchers from Anglia Ruskin University (ARU) and University College London Hospital (UCLH), tested the efficacy of combining phosphodiesterase type 5 (PDE5) inhibitors—familiar drugs primarily used for erectile dysfunction such as sildenafil (Viagra) and tadalafil (Cialis)—with selective estrogen receptor modulators (SERMs) like tamoxifen. The rationale for this combination emerged from extensive preclinical drug screening that identified both PDE5 inhibitors and SERMs as potent inhibitors of the profibrotic transformation of fibroblasts into myofibroblasts, the culprits behind plaque development and disease progression.
The clinical trial enrolled 133 men diagnosed with acute Peyronie’s disease and administered the pharmaceutical combo over a period of three months. Their outcomes were benchmarked against a control cohort receiving standard care regimens comprising high-dose vitamin E or no intervention. Importantly, the control group did not undergo surgical intervention to avoid confounding variables. The results decisively favored the combination therapy, with nearly 43% of treated patients reporting substantial improvement in penile curvature, an enhancement nearly threefold that observed in the control group, where only 15% showed improvement.
Equally striking was the significant reduction in pain during erections—a hallmarked symptom of acute PD. Patients in the combination group experienced a dramatic decline from 65% reporting painful erections at baseline to a mere 1.5% after three months of treatment. This contrasted sharply with the standard-care group’s moderate pain reduction from 50% to 27%. These findings suggest that early intervention with this drug combination not only halts fibrotic progression but also substantially alleviates acute symptomatology, greatly improving patient quality of life.
The scientific foundation for this clinical success lies in the prior laboratory efforts helmed by Professor Selim Cellek at ARU’s Fibrosis Research Group. Through a painstaking high-throughput screening of 1,953 FDA-approved compounds, his team identified a subset of drugs capable of interrupting the critical fibroblast-to-myofibroblast conversion. PDE5 inhibitors and SERMs emerged as the most promising agents, with synergistic effects when combined, surpassing the efficacy of individual administration. This translational bench-to-bedside approach exemplifies precision repurposing of existing therapeutics to address unmet clinical needs.
One of the major clinical challenges in Peyronie’s disease management is the absence of approved oral pharmacotherapies to proactively prevent disease evolution during the acute phase. The current standard practice involves watchful waiting until the disease stabilizes before considering invasive procedures such as intralesional injections or corrective surgery. This reactive approach often prolongs patient suffering and can result in irreversible anatomical deformity or sexual dysfunction.
Professor Cellek highlights that the favorable safety profiles and widespread clinical familiarity with PDE5 inhibitors and SERMs accentuate the viability of this therapeutic strategy for rapid clinical translation. Because these drugs are already extensively used for other indications, regulatory hurdles and drug development timelines could be substantially abbreviated. If larger, randomized controlled trials validate these initial positive results, early fibrosis-targeted intervention could revolutionize Peyronie’s disease treatment protocols.
UCLH’s Professor David Ralph underscores the significance of this study as the first clinical demonstration aligning with the molecular understanding of PD pathogenesis. His remarks emphasize that the combined therapy effectively inhibits the pathologic cellular transformation and plaque contraction, thus not merely managing symptoms but altering the disease trajectory itself. This breakthrough offers hope for patients historically limited to palliative measures and invasive surgical options.
The study ignites a hopeful prospect for accelerating future prospective trials, which are crucial to confirm efficacy, optimize dosing, and evaluate longer-term outcomes and safety. Moreover, insights gleaned from this research may extend to fibrotic disorders beyond Peyronie’s disease, signaling broader implications for antifibrotic pharmacotherapy. The potential for repurposing well-established medicines to target diverse fibrotic pathologies stands as a testament to the power of interdisciplinary translational research.
In summary, this pivotal investigation marks a vital step forward in sexual medicine. By simultaneously leveraging the antifibrotic properties of PDE5 inhibitors and SERMs, researchers have unveiled a compelling treatment paradigm for acute Peyronie’s disease that promises to transform clinical care. The future of PD management may witness a shift from passive observation to active fibrosis modulation, ultimately restoring function and reducing the profound psychological burden associated with this enigmatic disease.
As this innovative drug combination progresses towards wider clinical adoption, it affirms the value of drug repurposing as a cost-effective, rapid, and rational approach to address conditions with limited therapeutic options. The convergence of sophisticated molecular screening with rigorous clinical evaluation continues to illuminate pathways towards alleviating human suffering in complex diseases like Peyronie’s.
Subject of Research: People
Article Title: Evaluation of a combination of off-label PDE5 inhibitor and tamoxifen in acute Peyronie’s disease
News Publication Date: 15-May-2026
Web References: http://dx.doi.org/10.1093/jsxmed/qdag120
Keywords: Peyronie’s disease, fibrosis, phosphodiesterase type 5 inhibitors, selective estrogen receptor modulators, drug repurposing, sexual medicine, fibrosis inhibition, penile curvature, tamoxifen, sildenafil, tadalafil, clinical trial
Tags: clinical trials for PD treatmentcombination therapy for Peyronie’s diseaseearly-stage Peyronie’s disease interventionerectile dysfunction and Peyronie’s diseasefibrotic scar tissue in penismanaging penile curvature with drugsnovel pharmaceutical approaches to fibrotic disordersoff-label drug use in urologyPDE5 inhibitors and fibrotic diseasesildenafil repurposing for PDtamoxifen in penile fibrosisViagra for Peyronie’s disease treatment
